TransMedics Group, Inc. - Common Stock (TMDX)

Both have helped transform their respective industries.

The Hidden Gems team discusses the latest AI infrastructure deal between Meta Platforms and neocloud company Nebius, then delves into consumer spending via Dollar Tree's 2025 results.

TransMedics continues to reinvent the organ transplant industry, but the market insists the stock is "overvalued" now.

Four dominant, cash-generating compounders just went on sale. The fundamentals say the long-term story is only getting stronger.

The mid-cap healthcare specialist is definitely worth a second look.

Listen in as Motley Fool co-founder Tom Gardner and Chief Investment Officer Andy Cross talk about stocks!

It might be worth buying these companies before the market notices they are undervalued.

Are you looking for investment opportunities in 2026?

With great returns comes added volatility.

These businesses are innovators in their respective industries.

As the final trading days of 2025 approach, the Nasdaq has reached a staggering milestone that has both bulls and bears on edge. According to the latest settlement data released on December 15, 2025, total short interest across the Nasdaq exchange has surged to a record 18.38 billion shares.

TransMedics (TMDX) exemplifies Growth at a Reasonable Price (GARP) with strong revenue growth, solid industry valuation, and improving profitability in medical tech.

These companies are worth your attention.